

# EUR Research Information Portal

## Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of preb-high-density lipoproteins

**Published in:**  
Biochemical Journal

**Publication status and date:**  
Published: 01/01/2001

**DOI (link to publisher):**  
[10.1042/0264-6021:3600379](https://doi.org/10.1042/0264-6021:3600379)

**Document Version**  
Publisher's PDF, also known as Version of record

### Citation for the published version (APA):

Lie, J.T., Crom, R., Jauhiainen, M., Gent, T., van Haperen, R., Scheek, L.M., Jansen, H., Ehnholm, C., & Tol, A. (2001). Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of preb-high-density lipoproteins. *Biochemical Journal*, 360, 379-385. <https://doi.org/10.1042/0264-6021:3600379>

[Link to publication on the EUR Research Information Portal](#)

### Terms and Conditions of Use

Except as permitted by the applicable copyright law, you may not reproduce or make this material available to any third party without the prior written permission from the copyright holder(s). Copyright law allows the following uses of this material without prior permission:

- you may download, save and print a copy of this material for your personal use only;
- you may share the EUR portal link to this material.

In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may be allowed. Please check the terms and conditions of the specific license.

### Take-down policy

If you believe that this material infringes your copyright and/or any other intellectual property rights, you may request its removal by contacting us at the following email address: [openaccess.library@eur.nl](mailto:openaccess.library@eur.nl). Please provide us with all the relevant information, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint, we will make the material inaccessible and/or remove it from the website.

# Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre $\beta$ -high-density lipoproteins

Jessica LIE<sup>\*1</sup>, Rini DE CROM<sup>†‡1</sup>, Matti JAUHAINEN<sup>§</sup>, Teus VAN GENT<sup>\*</sup>, Rien VAN HAPEREN<sup>†</sup>, Leo SCHEEK<sup>\*</sup>, Hans JANSEN<sup>\*</sup>, Christian EHNHOLM<sup>§</sup> and Arie VAN TOL<sup>\*2</sup>

<sup>\*</sup>Department of Biochemistry, Cardiovascular Research Institute COEUR, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR Rotterdam, The Netherlands,

<sup>†</sup>MGC-Department of Cell Biology and Genetics, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR Rotterdam, The Netherlands, <sup>‡</sup>Department of Vascular

Surgery, Academic Hospital "Dijkzigt", Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands, and <sup>§</sup>Department of Biochemistry, National Public Health Institute, Mannerheimintie 166, FIN-03000 Helsinki, Finland

High-density lipoproteins (HDLs) are considered anti-atherogenic because they mediate peripheral cell cholesterol transport to the liver for excretion and degradation. An important step in this reverse cholesterol-transport pathway is the uptake of cellular cholesterol by a specific subclass of small, lipid-poor apolipoprotein A-I particles designated pre $\beta$ -HDL. The two lipid-transfer proteins present in human plasma, cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP), have both been implicated in the formation of pre $\beta$ -HDL. In order to investigate the relative contribution of each of these proteins, we used transgenic mouse models. Comparisons were made between human CETP transgenic mice (huCETP<sup>tg</sup>), human PLTP transgenic mice (huPLTP<sup>tg</sup>) and mice transgenic for both lipid-transfer proteins (huCETP<sup>tg</sup>/huPLTP<sup>tg</sup>). These

animals showed elevated plasma levels of CETP activity, PLTP activity or both activities, respectively. We evaluated the generation of pre $\beta$ -HDL in mouse plasma by immunoblotting and crossed immuno-electrophoresis. Generation of pre $\beta$ -HDL was equal in huCETP<sup>tg</sup> and wild-type mice. In contrast, in huPLTP<sup>tg</sup> and huCETP<sup>tg</sup>/huPLTP<sup>tg</sup> mice, pre $\beta$ -HDL generation was 3-fold higher than in plasma from either wild-type or huCETP<sup>tg</sup> mice. Our findings demonstrate that, of the two plasma lipid-transfer proteins, PLTP rather than CETP is responsible for the generation of pre $\beta$ -HDL. These data support the hypothesis of a role for PLTP in the initial stage of reverse cholesterol transport.

**Key words:** apoA-I, LCAT, lecithin:cholesterol acyltransferase, reverse cholesterol transport, transgenic mice.

## INTRODUCTION

Plasma levels of high-density lipoprotein (HDL) cholesterol correlate negatively with the risk of coronary artery disease, and raising HDL cholesterol levels by drug treatment results in prevention of coronary artery disease [1–4]. HDL is considered to protect against atherosclerosis via its role in reverse cholesterol transport [5]. This pathway involves the uptake of cholesterol from peripheral cells and subsequent transport and delivery to the liver for degradation and excretion. Recent data indicate that the ATP-binding cassette transporter A1 (ABCA1) plays a key role in the efflux of cholesterol from cells [6–8]. Patients suffering from Tangier disease, with a mutated form of the *ABCA1* gene, show premature atherosclerosis, providing compelling evidence for a substantial protective role of reverse cholesterol transport in the development of atherosclerosis. The initial extracellular acceptor of cellular cholesterol is a specific subclass of HDL, designated pre $\beta$ -HDL [9]. Cellular cholesterol taken up by pre $\beta$ -HDL is subsequently esterified by the action of lecithin:cholesterol acyltransferase (LCAT). As a consequence, pre $\beta$ -HDL matures into  $\alpha$ -HDL. Esterified cholesterol from  $\alpha$ -HDL can be taken up in the liver either directly by selective uptake or indirectly via low-density lipoproteins (LDLs). The indirect pathway follows transfer of cholesteryl esters to very-low-density lipoproteins (VLDLs) and LDLs by cholesteryl ester

transfer protein (CETP) [9,10]. Thus pre $\beta$ -HDL is a key factor in reverse cholesterol transport.

Although the plasma lipid-transfer proteins phospholipid transfer protein (PLTP) and CETP have non-overlapping functions [11], studies both *in vitro* and *in vivo* have demonstrated that CETP and PLTP may both contribute to the formation of pre $\beta$ -HDL [12–18].

PLTP is involved in the transfer of phospholipids between lipoproteins and in the remodelling of HDL [19–21]. Its physiological function has been studied in several mouse models [12,22–24]. PLTP-deficient mice show an impaired transfer of post-lipolytic VLDL surface remnant phospholipids to HDL and, as a consequence, decreased plasma HDL levels [21]. In PLTP transgenic mice with slightly elevated PLTP activity levels minor effects on plasma lipids and lipoprotein patterns were found [15,23]. However, in double-transgenic mice expressing both PLTP and human apolipoprotein A-I (apoA-I), pre $\beta$ -HDL levels were increased [23]. We generated transgenic human PLTP mice that show a moderate, though substantial overexpression of PLTP (2.5–3-fold in hemizygous transgenic mice) [12]. Plasma from these mice has an increased ability to generate pre $\beta$ -HDL and prevents cholesterol accumulation in macrophages to a greater extent than plasma from wild-type animals. From these studies, we concluded that PLTP could have anti-atherogenic properties via its ability to generate pre $\beta$ -HDL.

Abbreviations used: apoA-I, apolipoprotein A-I; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LCAT, lecithin:cholesterol acyltransferase; LDL, low-density lipoprotein; PLTP, phospholipid transfer protein; VLDL, very-low-density lipoprotein; huCETP<sup>tg</sup> mice, mice expressing the human CETP transgene; huPLTP<sup>tg</sup> mice, mice expressing the human PLTP transgene; huCETP<sup>tg</sup>/huPLTP<sup>tg</sup> mice, mice expressing the human CETP and PLTP transgenes.

<sup>1</sup> These authors have contributed equally to this paper.

<sup>2</sup> To whom correspondence should be addressed (e-mail vantol@bc1.fgg.eur.nl).

Both CETP and PLTP belong to a family of lipid-transfer/lipopolysaccharide-binding proteins [10,25]. Although CETP has profound effects on lipoprotein metabolism in humans, some species, including mice, lack CETP activity [26]. *In vitro* studies demonstrate that CETP transfers cholesteryl esters from HDL to apoB-containing lipoproteins in exchange for triglycerides, whereas PLTP does not transfer neutral lipids [5]. In addition to PLTP, CETP is able to transfer phospholipids *in vitro*, but it is unknown whether they share this ability *in vivo*.

In the present study we evaluated the relative contributions of CETP and PLTP to the formation of pre $\beta$ -HDL. To this end, we made comparisons between various lines of transgenic mice expressing human CETP, human PLTP or both lipid-transfer proteins.

## MATERIALS AND METHODS

### Breeding and treatment of transgenic mice

Human CETP transgenic mice (line 5203; huCETP<sub>tg</sub>) were kindly donated by Dr A. R. Tall (Columbia University, New York, NY, U.S.A.) [27] and have a C57BL/6 background. Human PLTP transgenic mice (huPLTP<sub>tg</sub>) were generated as described previously [12] and were backcrossed to the C57BL/6 background for at least seven generations. Mice expressing the human CETP and PLTP transgenes (huCETP<sub>tg</sub>/huPLTP<sub>tg</sub>) were obtained by crossbreeding huCETP<sub>tg</sub> and huPLTP<sub>tg</sub> mice. Both transgenes had the natural flanking sequences, including the autologous promoters. Animals were housed in a temperature-controlled room operating under a 12 h:12 h light/dark cycle. Animals were fed regular chow and water *ad libitum*.

Blood samples were collected, from animals that had been fasted overnight, from the orbital plexus by using Vitrex<sup>®</sup> sodium-heparinized micropipettes (80 i.u.; Modulohm A/S, Copenhagen, Denmark) and were immediately stored on ice. Blood was centrifuged at 1500  $g_{max}$  for 15 min at 4 °C. Plasma was either used directly or stored in small aliquots at -80 °C before analysis. All animal experiments were done in compliance with the Guidelines of the Ethical Committee on the Use of Laboratory Animals of the Erasmus University Rotterdam (protocol no. 120.99.05) and with the European Committee Standards on the care and use of laboratory animals (Ministry of Welfare, Health and Cultural Affairs, The Netherlands).

### DNA analysis

Genomic DNA was isolated from tail clips of 10 day-old mice and analysed for the presence of the huCETP transgene and/or huPLTP transgene by PCR analysis. Conditions and primers were as follows: huCETP, sense primer, 5'-CACTAGCCC-AGAGAGAGGAGTGC-3', antisense primer 5'-CTGAGCC-CAGCCGCACACTAAC-3', 28 cycles (94 °C, 1 min; 65 °C, 1 min; 72 °C, 1.5 min); huPLTP, sense primer, 5'-GCCACA-GCAGGAGCTGATGC-3', antisense primer, 5'-GCGGATGG-ACACACCCTCAGC-3', 28 cycles (94 °C, 1 min; 65 °C, 1 min; 72 °C, 2 min).

### Plasma activity assays

CETP and PLTP assays were performed according to Speijer et al. [28]. CETP activity was determined by measuring the rate of transfer/exchange of radiolabelled cholesteryl oleate between exogenously added human LDL and HDL. PLTP activity was determined by measuring the transfer of radiolabelled dipalmitoyl phosphatidylcholine (DPPC) from liposomes {composed of egg lecithin (Amersham, Little Chalfont, Bucks., U.K.) and

[<sup>3</sup>H]DPPC as a tracer} to exogenously added human HDL (density, 1.063 g/ml <  $d$  < 1.21 g/ml). CETP and PLTP activities are expressed as a percentage of the human reference plasma: 100% is equivalent to the following activities; CETP, 215.6 nmol/ml per h; PLTP, 13.9  $\mu$ mol/ml per h.

Hepatic lipase activity was measured as described by Jansen et al. [29]. LCAT activity was determined by measuring the formation of radiolabelled cholesteryl ester after addition of 10 or 20  $\mu$ l of mouse plasma to excess heat-inactivated plasma containing [<sup>3</sup>H]cholesterol (Amersham) [30]. Hepatic lipase and LCAT activities are expressed as a percentage of plasma from wild-type mice (C57BL/6).

### Quantification of plasma lipids and apolipoproteins

Plasma lipids were determined enzymically with commercially available kits: total cholesterol with the F-chol kit of Boehringer Mannheim (Mannheim, Germany) after hydrolysis of cholesteryl esters with cholesteryl esterase from *Candida cylindracea* (Boehringer Mannheim). Phospholipids were measured with the PAP150 kit from BioMérieux (Lyon, France). Plasma triglycerides were measured with the Sigma GPO-Trinder kit (procedure no. 337-B; Sigma, St. Louis, MO, U.S.A.). Mouse apoA-I was quantified by sandwich ELISA as reported in [12].

### Gel-filtration chromatography of mouse plasma lipoproteins

Lipoprotein profiles were determined by gel filtration of freshly isolated plasma on two HR10/30 FPLC columns in tandem (Superose 6 pregrade and Superdex 200 pregrade; Pharmacia Biotech, Uppsala, Sweden). The columns were equilibrated with 2 mM NaH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub>, pH 7.4, containing 0.9% NaCl (w/v), 0.02% NaN<sub>3</sub> (w/v) and 5 mM EDTA. Combined plasma samples from four to seven mice were passed through 0.45  $\mu$ m filters from Millipore S. A. (Molsheim, France), and 0.5 ml were subjected to gel filtration. The columns were run at 4 °C with a flow rate of 0.1 ml/min. Fractions of 0.8 ml were collected. Recoveries were > 90% for all analyses.

### Quantification of pre $\beta$ -HDL

Mouse plasma samples were either frozen directly or incubated in the presence of iodoacetate in order to measure pre $\beta$ -HDL formation. Incubation conditions were as reported in [12]. Plasma samples were separated by agarose-gel electrophoresis under non-reducing, non-denaturing conditions and low ionic strength according to the manufacturer's instructions (Paragon Lipo system; Beckman, Fullerton, CA, U.S.A.) to separate pre $\beta$ - and  $\alpha$ -migrating HDL. Proteins were transferred by capillary blotting to nitrocellulose membranes (Schleicher & Schuell NY 13N 6214/95, Dassel, Germany). Membranes were blocked for 1 h in 5% (w/v) skimmed milk in 20 mM Tris/HCl, pH 7.4/0.5 M NaCl. Membranes were subsequently incubated with an affinity-purified rabbit anti-mouse apoA-I polyclonal antibody. <sup>125</sup>I-labelled donkey anti-rabbit F(ab)<sub>2</sub> fragment (17 Ci/g; Amersham) was used as the detection antibody. The relative abundance of apo-AI among the  $\alpha$ - or pre $\beta$ -HDL species was calculated by quantitative scanning using a PhosphorImager (GS-363; BioRad). Crossed immuno-electrophoresis was performed as described in [12].

### Statistical analysis


Data are expressed as means  $\pm$  S.D. Differences between two genotypes were analysed by two-sample Wilcoxon rank-sum

tests. Differences between three genotypes were analysed by ANOVA followed by Bonferroni correction.

## RESULTS


### Plasma activities of CETP and PLTP

CETP activities were measured in plasma from huCETPtg mice and huCETPtg/huPLTPtg mice (Figure 1A). CETP activity in wild-type mice was virtually absent (< 4% of human reference




**Figure 1 Plasma CETP and PLTP activities in transgenic mice**

Plasma activities were determined in individual plasma samples from huCETPtg mice ( $n = 12$ ) and huCETPtg/huPLTPtg mice ( $n = 10$ ). Values are expressed as a percentage of human reference plasma (means  $\pm$  S.D.). (A) CETP activity: 100% human reference plasma is equivalent to CETP activity of 215.6 nmol/ml per h; \* $P < 0.01$  compared with huCETPtg mice (rank-sum test). (B) PLTP activity: 100% human reference plasma is equivalent to PLTP activity of 13.9  $\mu$ mol/ml per h; \*\* $P < 0.0001$  compared with huCETPtg mice (rank-sum test).




**Figure 2 Plasma hepatic lipase and LCAT activities in transgenic mice**

Plasma activities were measured in individual plasma samples from wild-type mice (wt;  $n = 16$ ), huCETPtg mice ( $n = 12$ ), huPLTPtg mice ( $n = 8$ ) and huCETPtg/huPLTPtg mice ( $n = 10$ ). Values are means  $\pm$  S.D. and are expressed as a percentage of the wild-type value. (A) Hepatic lipase activity: 100% hepatic lipase activity of the wild-type is equivalent to 56.1 nmol/ml per h; \* $P < 0.05$ , significantly different from huCETPtg mice (ANOVA followed by Bonferroni correction). (B) LCAT activity: 100% LCAT activity of the wild-type is equivalent to 71.3 nmol/ml per h. Transgenic mice showed similar LCAT activities (not significantly different).



**Figure 3 Lipoprotein profiles of plasma from transgenic mice**

Equal amounts of plasma from either huCETPtg mice ( $n = 4$ ) or huCETPtg/huPLTPtg mice ( $n = 7$ ) were pooled and subjected to gel filtration on Superose 6 and Superdex 200 columns connected in tandem as described in the Materials and methods section. Fractions were analysed for (A) cholesterol, (B) phospholipids, (C) CETP activity and (D) PLTP activity. Fractions 1–4 contain VLDL, 5–10 contain LDL, 11–19 contain HDL and 20–25 contain lysophosphatidylcholine bound to albumin.



**Figure 4** HDL subfractions of incubated plasma samples from transgenic mice

Analysis of HDL subfractions was performed in plasma from huCETPtg (lane 1), huCETPtg/huPLTPtg (lane 2), huPLTPtg (lane 3) and wild-type (lane 4) mice. Mouse plasma (10  $\mu$ l) was incubated in the presence of an LCAT inhibitor (1 mM iodoacetic acid) at 37 °C for 3 h. Equal amounts of plasma were run on a 0.5% agarose gel, transferred to nitrocellulose membranes and subjected to immunoblotting using rabbit anti-mouse apoA-I IgG.

plasma). HuCETPtg mice had a CETP activity of  $144 \pm 34\%$  of human reference plasma whereas CETP activity in huCETPtg/huPLTPtg mice was about 20% lower ( $P < 0.01$ ).

PLTP activity levels were measured in plasma samples of huCETPtg mice and huCETPtg/huPLTPtg mice (Figure 1B). The PLTP activity in plasma of huCETPtg mice was somewhat higher than human PLTP activity levels:  $136 \pm 16\%$  of human reference plasma, which is in agreement with measurements in wild-type mice [12]. The PLTP activity in the huCETPtg/huPLTPtg mice was 4-fold higher (Figure 1B). This activity level closely resembles the level reported previously for huPLTPtg mice [12].


#### Plasma hepatic lipase activity and LCAT activity

Mice express hepatic lipase activity in plasma, even without intravenous injection of heparin [31]. We investigated whether any differences in the activity of hepatic lipase in plasma between huCETPtg mice and huCETPtg/huPLTPtg mice could be observed. As shown in Figure 2(A), the huCETPtg/huPLTPtg mice had lower levels of hepatic lipase activity than huCETPtg mice ( $P < 0.05$ ). Hepatic lipase activity in the huPLTPtg mice was  $91 \pm 27\%$  of wild-type mouse plasma.

In plasma, pre $\beta$ -HDL matures into  $\alpha$ -HDL by the action of LCAT. The levels of LCAT activity were not significantly different between the three tested genotypes (Figure 2B).

#### Lipid and lipoprotein analysis

Plasma samples from either huCETPtg or huCETPtg/huPLTPtg animals were analysed by gel-filtration chromatography to examine their lipoprotein profiles. Cholesterol and phospholipid contents as well as CETP and PLTP activities were determined in all fractions (Figure 3). In unfractionated plasma, huCETPtg/huPLTPtg mice had lower levels of plasma cholesterol than huCETPtg mice ( $1.09 \pm 0.15$  mM,  $n = 9$ , versus  $1.43 \pm 0.16$  mM,  $n = 11$ ;  $P < 0.01$ ), whereas triglyceride levels were



**Figure 5** Crossed immuno-electrophoresis of incubated plasma samples from transgenic mice

Plasma samples from transgenic mice were incubated as described in the legend of Figure 4 and in the Materials and methods section. Subsequently, 5  $\mu$ l aliquots were applied to agarose gels for the first dimension, followed by electrophoresis into an anti-mouse apoA-I-containing gel for the second dimension. (A) Wild-type mice, (B) huCETPtg mice, (C) huPLTPtg mice and (D) huCETPtg/huPLTPtg mice.

similar (huCETPtg mice,  $0.38 \pm 0.14$ ,  $n = 5$ ; huCETPtg/huPLTPtg mice,  $0.48 \pm 0.25$ ,  $n = 5$ , not statistically significant). As evident from Figure 3(A), which shows the cholesterol profile, this is due to a decrease in HDL cholesterol. The phospholipids have a similar profile, showing a decrease in HDL phospholipids due to PLTP overexpression (Figure 3B). The phospholipids present in fractions 20–25 represent lysophosphatidylcholine bound to albumin. In both groups of mice CETP activity eluted in fractions 14–18, corresponding to the position of HDL particles (Figure 3C). PLTP activity eluted in fractions 11–15, the position of relatively large HDLs (Figure 3D), a situation also found in humans.

#### Effects of huPLTP and huCETP expression on pre $\beta$ -HDL formation


To investigate the formation of pre $\beta$ -HDL, incubated plasma samples from wild-type, huCETPtg, huPLTPtg and huCETPtg/huPLTPtg mice were subjected to agarose-gel electrophoresis followed by immunoblotting. Upon incubation, the levels of pre $\beta$ -HDL increased in mice expressing human PLTP, whereas neither wild-type nor huCETPtg mice showed appreciable levels of pre $\beta$ -HDL formation (Figure 4). In order to quantify pre $\beta$ -HDL formation, crossed immuno-electrophoresis experiments were performed (Figure 5). The results corroborated the findings from the immunoblotting experiments, since incubated samples from mice expressing human PLTP showed relatively

**Table 1** Pre $\beta$ -HDL levels in plasma of transgenic mice

Plasma samples were incubated as described in the legend of Figure 4. Values represent the relative and absolute amounts of pre $\beta$ -HDL in plasma before and after incubation at 37 °C for 3 h. These were calculated, as described in the legend of Figure 6, from the percentage of apoA-I present in pre $\beta$ -HDL and the total plasma apoA-I concentrations respectively. Values are means  $\pm$  S.D. ( $n = 3$ ).

Genotype	Total plasma apoA-I (mg/ml)	Relative pre $\beta$ -HDL (% of plasma apoA-I)		Absolute pre $\beta$ -HDL ( $\mu$ g of apoA-I/ml)	
		Pre-incubation	Post-incubation	Pre-incubation	Post-incubation
Wild-type	1.0 $\pm$ 0.07	3.7 $\pm$ 0.9	7.3 $\pm$ 0.5	36.7 $\pm$ 12.1	73.5 $\pm$ 10.2
huCETPtg	0.88 $\pm$ 0.05	5.0 $\pm$ 0.8	7.3 $\pm$ 0.5	44.1 $\pm$ 10.9	64.5 $\pm$ 8.6
huPLTPtg	0.73 $\pm$ 0.24	6.0 $\pm$ 0.8	16.7 $\pm$ 0.9*	44.2 $\pm$ 14.8	125.1 $\pm$ 49.4*
huCETPtg/huPLTPtg	0.7 $\pm$ 0.09	7.3 $\pm$ 1.7	17.3 $\pm$ 1.3*	52.3 $\pm$ 20.2	121.2 $\pm$ 22.7*

\* Significantly different from wild-type mice,  $P < 0.05$  (rank-sum test).

**Figure 6** Pre $\beta$ -HDL formation in plasma samples from transgenic mice

Plasma samples from wild-type, huCETPtg, huPLTPtg and huCETPtg/huPLTPtg mice were incubated as described in the legend of Figure 4. Values represent the differences in the relative amounts of pre $\beta$ -HDL, expressed as a percentage of total plasma apoA-I, before and after incubation. These were calculated based on the areas underneath the peaks of pre $\beta$ -HDL and  $\alpha$ -HDL following crossed immuno-electrophoresis. Values are means  $\pm$  S.D.; \* $P < 0.001$  compared with both wild-type and huCETPtg mice (ANOVA followed by Bonferroni correction).

higher pre $\beta$ -HDL peaks. Measurements of pre $\beta$ -HDL in plasma without incubation revealed no significant differences between the genotypes tested (Table 1). However, in incubated samples, significant differences were observed in both relative and absolute concentrations of pre $\beta$ -HDL between huPLTPtg mice on the one hand and wild-type or huCETPtg mice on the other (Table 1). Using the data in Table 1, the formation of pre $\beta$ -HDL during incubation of plasma was calculated (see Figure 6). Pre $\beta$ -HDL

formation in plasma from huCETPtg/huPLTPtg and huPLTPtg mice was at least 3-fold higher than in plasma from wild-type mice and huCETPtg mice. Thus CETP does not seem to make a substantial contribution towards the formation of pre $\beta$ -HDL.

## DISCUSSION

CETP and PLTP are important factors in modulating plasma lipid transport and both have been implicated in the generation of pre $\beta$ -HDL particles [12,13,15,16,18]. However, to date their relative importance in this process has not been established unequivocally. This is due to the fact that all available data originate from studies in which only one of the lipid-transfer proteins was investigated. Besides, the use of different models, either *in vivo* or *in vitro*, as well as the use of different techniques, hampers a comparative evaluation. For this reason we have used transgenic mouse models with relatively modest overexpression of the human PLTP and/or CETP proteins, enabling us to make direct comparisons of pre $\beta$ -HDL formation.

The huPLTPtg mice that we used as the parental strain to generate huPLTPtg/huCETPtg mice have been described previously [12]. These mice have approx. 3-fold higher plasma PLTP activity levels than wild-type mice. This results in more pronounced effects on plasma lipids compared with those reported by other groups using transgenic mice with low levels of PLTP expression [15,23]. Strong overexpression, as found in mice expressing human PLTP after transfection with adenoviral constructs, was avoided since this causes extreme effects on lipoprotein metabolism, resulting in a near absence of plasma cholesterol [22,24].

The huCETPtg mice that were used in the present study were created and characterized by Jiang et al. [27]. In addition to a human CETP mini-gene, these mice have the natural flanking DNA sequences of the human CETP gene (3.2 kb upstream and 2.0 kb downstream sequences). This construct results in CETP plasma activity levels that are much lower than other CETP-overexpression models [32,33]. Moderate expression of CETP in the huCETPtg mice used in the present study was confirmed by measuring CETP mass by ELISA. Concentrations ranged from 2.7 to 4.1  $\mu$ g/ml in plasma samples from huCETPtg mice (T. van Gent, J. T. Lie and A. van Tol, unpublished work), which is about 1.5-fold higher than values found in human plasma [34]. Thus this mouse model shows modest CETP expression and resembles the human condition in terms of plasma CETP activity and mass. In both models, expression of the transgene resulted in distinct effects on plasma lipids/lipoproteins.

In order to evaluate possible interactions between the two lipid-transfer proteins, in terms of either their respective transfer

activities or the formation of pre $\beta$ -HDL, we extended our studies with double-transgenic animals, huCETPtg/huPLTPtg mice. This model resembles the situation in humans since, in contrast to mice, humans express both plasma transfer proteins.

huCETPtg and huCETPtg/huPLTPtg mice showed a small difference in plasma CETP activity levels. The expression of the human PLTP gene is associated with a decrease in CETP activity of about 20%. This decrease is confirmed on analysis of the CETP activity profiles after gel filtration (Figure 3C). This effect could be the result of a direct effect of overexpression of human PLTP on the level of expression of the CETP transgene. An alternative explanation is that PLTP expression causes a lower plasma HDL concentration. Since HDL is the carrier of CETP, this could eventually result in a decrease in CETP levels. The profiles show that CETP activity elutes at a position corresponding to that of HDL particles.

PLTP activity measured in huCETPtg/huPLTPtg mice equals the PLTP activity in the huPLTPtg mice described previously [12]. PLTP activity in huCETPtg mice was comparable with that in wild-type mice. Therefore CETP does not seem to affect the activity of the endogenous mouse PLTP in plasma. In comparison with the lipoprotein profile found in huPLTPtg mice [12], huCETPtg/huPLTPtg mice have somewhat smaller HDLs, which is in agreement with previous studies in transgenic mice expressing human CETP [35]. The activity profiles of PLTP in huCETPtg mice and huCETPtg/huPLTPtg mice were measured after gel filtration of plasma (Figure 3D). The profiles show that PLTP activity elutes at the position corresponding to relatively large-sized HDL particles in both groups of mice. Thus CETP and PLTP co-elute with particles of different sizes, a situation also found in humans [28].

The main purpose of the present study was to determine the relative contribution of PLTP and CETP to pre $\beta$ -HDL generation. We evaluated the formation of pre $\beta$ -HDL in plasma using two different methods and demonstrated that pre $\beta$ -HDL formation is increased in plasma from transgenic mice expressing human PLTP, whereas expression of human CETP did not affect this process. These findings cannot be attributed to differences in preference of the transfer proteins towards human versus mouse HDL, since incubations of plasma from huCETPtg mice with freshly isolated human HDL did not show formation of pre $\beta$ -HDL (J. T. Lie, R. de Crom, M. Jauhiainen, T. van Gent, R. van Haperen, L. M. Scheek, C. Ehnholm and A. van Tol, unpublished work).

LCAT activity was similar in plasma of the various transgenic mice, which implies that a difference in maturation of pre $\beta$ -HDL into  $\alpha$ -HDL is unlikely. Therefore differences in LCAT activity cannot explain the observed distinctions in pre $\beta$ -HDL formation.

The involvement of hepatic lipase in the formation of pre $\beta$ -HDL has been suggested [36]. In humans, virtually all hepatic lipase is bound to liver endothelial cells, whereas in mice hepatic lipase circulates in plasma [31]. It was therefore important to know whether plasma from huCETPtg/huPLTPtg mice displayed higher hepatic lipase activity than plasma from huCETPtg mice. Hepatic lipase activity was found to be lower in plasma from huCETPtg/huPLTPtg compared with plasma from huCETPtg mice, so this activity cannot explain the observed differences in pre $\beta$ -HDL generation.

Other groups have reported a role for CETP in pre $\beta$ -HDL formation [13,17,18]. Kunitake et al. [13] showed that pre $\beta$ -HDL formation is stimulated by CETP *in vitro*. Francone et al. [18], using double-transgenic animals that overexpressed CETP (driven by the metallothionein promoter) as well as human apoA-I, observed increased levels of pre $\beta$ -HDL in these mice. In the mouse models used here, CETP expression was driven by its

native promoter and CETP levels and activities were comparable with those in human plasma. An increase in the generation of relative and absolute plasma levels of pre $\beta$ -HDL formation was only observed in huPLTPtg mice. Despite lower HDL concentrations in huCETPtg/huPLTPtg mice compared with huCETPtg mice, plasma of huCETPtg/huPLTPtg mice had a greater ability to produce pre $\beta$ -HDL. This finding of a combination of low HDL cholesterol levels and increased pre $\beta$ -HDL formation was also observed in huPLTPtg mice [12], as well as in mice using adenoviral overexpression of PLTP [22,24].

Although CETP and PLTP share similar structural properties and belong to the same gene family, it has been found that they have non-overlapping functions *in vivo* [11]. The roles of the HDL modulators CETP and PLTP in atherosclerosis have not yet been elucidated. CETP participates in reverse cholesterol transport, a function that may mean it has anti-atherogenic potential [10]. On the other hand, CETP mediates the exchange of cholesteryl esters in HDL for triglycerides in VLDL. This process leads to a decrease in HDL cholesterol and to an increase in potentially pro-atherogenic VLDL and LDL cholesterol [37]. Although substantial overexpression of human CETP was reported to cause increased susceptibility to diet-induced atherosclerosis [32], CETP has been proved to be anti-atherogenic in other (compound) transgenic mouse models [38,39]. In rats, high-level expression of human CETP is highly atherogenic [33], whereas in rabbits inhibition of CETP proved to be anti-atherogenic [40]. The impact of CETP on atherosclerosis in humans remains inconclusive [37]. The present study supports the notion that PLTP, rather than CETP, is responsible for the generation of pre $\beta$ -HDL. The impact of PLTP on diet-induced atherosclerosis will be the subject of future investigations.

This research was supported by a grant from the Netherlands Heart Foundation (98.088). We thank Ina Kalkman and Jari Metso for expert technical assistance.

## REFERENCES

- 1 Tall, A. R. (1990) Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. *J. Clin. Invest.* **86**, 379–384
- 2 Gordon, D. J. and Rifkind, B. M. (1989) High-density lipoprotein – the clinical implications of recent studies. *N. Engl. J. Med.* **321**, 1311–1316
- 3 Miller, N. E. (1987) Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. *Am. Heart J.* **113**, 589–597
- 4 Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G. et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N. Engl. J. Med.* **341**, 410–418
- 5 Fielding, C. J. and Fielding, P. E. (1995) Molecular physiology of reverse cholesterol transport. *J. Lipid Res.* **36**, 211–228
- 6 Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Plette, J. C., Deleuze, J. F., Brewer, H. B., Duverger, N., Denefle, P. and Assmann, G. (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat. Genet.* **22**, 352–355
- 7 Bodzioch, M., Orso, E., Klucken, J., Langmann, T., Bottcher, A., Diederich, W., Drobnik, W., Barlage, S., Buchler, C., Porsch-Ozcurumez, M. et al. (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. *Nat. Genet.* **22**, 347–351
- 8 Schmitz, G., Kaminski, W. E., Porsch-Ozcurumez, M., Klucken, J., Orso, E., Bodzioch, M., Buchler, C. and Drobnik, W. (1999) ATP-binding cassette transporter A1 (ABCA1) in macrophages: a dual function in inflammation and lipid metabolism? *Pathobiology* **67**, 236–240
- 9 Barter, P. J. and Rye, K. A. (1996) High density lipoproteins and coronary heart disease. *Atherosclerosis* **121**, 1–12
- 10 Bruce, C., Chouinard Jr, R. A. and Tall, A. R. (1998) Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. *Annu. Rev. Nutr.* **18**, 297–330

- 11 Kawano, K., Qin, S. C., Lin, M., Tall, A. R. and Jiang, X. (2000) Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions *in vivo*. *J. Biol. Chem.* **275**, 29477–29481
- 12 van Haperen, R., van Tol, A., Vermeulen, P., Jauhiainen, M., van Gent, T., van den Berg, P., Ehnholm, S., Grosveld, F., van der Kamp, A. and de Crom, R. (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. *Arterioscler. Thromb. Vasc. Biol.* **20**, 1082–1088
- 13 Kunitake, S. T., Mendel, C. M. and Hennessy, L. K. (1992) Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. *J. Lipid Res.* **33**, 1807–1816
- 14 Rye, K. A., Jauhiainen, M., Barter, P. J. and Ehnholm, C. (1998) Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. *J. Lipid Res.* **39**, 613–622
- 15 Albers, J. J., Tu, A. Y., Paigen, B., Chen, H., Cheung, M. C. and Marcovina, S. M. (1996) Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. *Int. J. Clin. Lab. Res.* **26**, 262–267
- 16 Lusa, S., Jauhiainen, M., Metso, J., Somerharju, P. and Ehnholm, C. (1996) The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. *Biochem. J.* **313**, 275–282
- 17 Rye, K. A., Hime, N. J. and Barter, P. J. (1997) Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. *J. Biol. Chem.* **272**, 3953–3960
- 18 Francone, O. L., Royer, L. and Haghpassand, M. (1996) Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. *J. Lipid Res.* **37**, 1268–1277
- 19 Jauhiainen, M., Metso, J., Pahlman, R., Blomqvist, S., van Tol, A. and Ehnholm, C. (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. *J. Biol. Chem.* **268**, 4032–4036
- 20 Huuskonen, J. and Ehnholm, C. (2000) Phospholipid transfer protein in lipid metabolism. *Curr. Opin. Lipidol.* **11**, 285–289
- 21 Jiang, X. C., Bruce, C., Mar, J., Lin, M., Ji, Y., Francone, O. L. and Tall, A. R. (1999) Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. *J. Clin. Invest.* **103**, 907–914
- 22 Ehnholm, S., van Dijk, K. W., van 't Hof, B., van der Zee, A., Olkkonen, V. M., Jauhiainen, M., Hofker, M., Havekes, L. and Ehnholm, C. (1998) Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. *J. Lipid Res.* **39**, 1248–1253
- 23 Jiang, X., Francone, O. L., Bruce, C., Milne, R., Mar, J., Walsh, A., Breslow, J. L. and Tall, A. R. (1996) Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. *J. Clin. Invest.* **98**, 2373–2380
- 24 Foger, B., Santamarina-Fojo, S., Shamburek, R. D., Parrot, C. L., Talley, G. D. and Brewer Jr, H. B. (1997) Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. *J. Biol. Chem.* **272**, 27393–27400
- 25 Tall, A. R., Jiang, X., Luo, Y. and Silver, D. (2000) 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* **20**, 1185–1188
- 26 Ha, Y. C. and Barter, P. J. (1982) Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. *Comp. Biochem. Physiol. B* **71**, 265–269
- 27 Jiang, X. C., Agellon, L. B., Walsh, A., Breslow, J. L. and Tall, A. (1992) Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. *J. Clin. Invest.* **90**, 1290–1295
- 28 Speijer, H., Groener, J. E., van Ramshorst, E. and van Tol, A. (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. *Atherosclerosis* **90**, 159–168
- 29 Jansen, H., Lammers, R., Baggen, M. G., Wouters, N. M. and Birkenhager, J. C. (1989) Circulating and liver-bound salt-resistant hepatic lipases in the golden hamster. *Biochim. Biophys. Acta.* **1001**, 44–49
- 30 Joles, J. A., Willekes-Koolschijn, N., Scheek, L. M., Koomans, H. A., Rabelink, T. J. and van Tol, A. (1994) Lipoprotein phospholipid composition and LCAT activity in nephrotic and albuminemic rats. *Kidney Int.* **46**, 97–104
- 31 Peterson, J., Bengtsson-Olivecrona, G. and Olivecrona, T. (1986) Mouse preheparin plasma contains high levels of hepatic lipase with low affinity for heparin. *Biochim. Biophys. Acta.* **878**, 65–70
- 32 Marotti, K. R., Castle, C. K., Boyle, T. P., Lin, A. H., Murray, R. W. and Melchior, G. W. (1993) Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. *Nature (London)* **364**, 73–75
- 33 Herrera, V. L., Makrides, S. C., Xie, H. X., Adari, H., Krauss, R. M., Ryan, U. S. and Ruiz-Opazo, N. (1999) Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. *Nat. Med.* **5**, 1383–1389
- 34 Marcel, Y. L., McPherson, R., Hogue, M., Czarnicka, H., Zawadzki, Z., Weech, P. K., Whitlock, M. E., Tall, A. R. and Milne, R. W. (1990) Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. *J. Clin. Invest.* **85**, 10–17
- 35 Hayek, T., Azrolan, N., Verdery, R. B., Walsh, A., Chajek-Shaul, T., Agellon, L. B., Tall, A. R. and Breslow, J. L. (1993) Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. *J. Clin. Invest.* **92**, 1143–1152
- 36 Barrans, A., Collet, X., Barbaras, R., Jaspard, B., Manent, J., Vieu, C., Chap, H. and Perret, B. (1994) Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to *in vitro* incubation with lipases. *J. Biol. Chem.* **269**, 11572–11577
- 37 Barter, P. (2000) CETP and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **20**, 2029–2031
- 38 Hayek, T., Masucci-Magoulas, L., Jiang, X., Walsh, A., Rubin, E., Breslow, J. L. and Tall, A. R. (1995) Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. *J. Clin. Invest.* **96**, 2071–2074
- 39 Foger, B., Chase, M., Amar, M. J., Vaisman, B. L., Shamburek, R. D., Paigen, B., Fruchart-Najib, J., Paiz, J. A., Koch, C. A., Hoyt, R. F. et al. (1999) Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. *J. Biol. Chem.* **274**, 36912–36920
- 40 Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K. and Shinkai, H. (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. *Nature (London)* **406**, 203–207